1-2 of 2
Shailaja Uttamsingh, PhD
Close
Sort by
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Shailaja Uttamsingh, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 449.
https://doi.org/10.1182/blood-2018-99-110213
Published: 2018
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, Fontanet Bijou, MD, Vincent Ribrag, MD, Julio C. Chavez, MD, Thomas E. Witzig, MD, David J. Andorsky, MD, Leonard M. Klein, MD, Daniel Greenwald, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Shailaja Uttamsingh, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Tianlei Chen, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2018-99-114409
Published: 2018